Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

COCH vs LNTH vs MDT vs RMD vs BSX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
COCH
Envoy Medical, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$13M
5Y Perf.-93.5%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$6.06B
5Y Perf.+292.7%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$97.62B
5Y Perf.-41.8%
RMD
ResMed Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$30.12B
5Y Perf.+10.0%
BSX
Boston Scientific Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$80.15B
5Y Perf.+23.7%

COCH vs LNTH vs MDT vs RMD vs BSX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
COCH logoCOCH
LNTH logoLNTH
MDT logoMDT
RMD logoRMD
BSX logoBSX
IndustryMedical - DevicesDrug Manufacturers - Specialty & GenericMedical - DevicesMedical - Instruments & SuppliesMedical - Devices
Market Cap$13M$6.06B$97.62B$30.12B$80.15B
Revenue (TTM)$241K$1.55B$35.48B$5.54B$20.07B
Net Income (TTM)$-24M$279M$4.61B$1.52B$2.89B
Gross Margin-262.7%60.5%61.9%61.7%69.0%
Operating Margin-92.4%18.8%17.9%34.3%19.8%
Forward P/E17.7x13.8x18.6x16.0x
Total Debt$919K$738K$28.52B$852M$12.42B
Cash & Equiv.$4M$359M$2.22B$1.21B$2.04B

COCH vs LNTH vs MDT vs RMD vs BSXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

COCH
LNTH
MDT
RMD
BSX
StockApr 21May 26Return
Envoy Medical, Inc. (COCH)1006.5-93.5%
Lantheus Holdings, … (LNTH)100392.7+292.7%
Medtronic plc (MDT)10058.2-41.8%
ResMed Inc. (RMD)100110.0+10.0%
Boston Scientific C… (BSX)100123.7+23.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: COCH vs LNTH vs MDT vs RMD vs BSX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT and BSX are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Boston Scientific Corporation is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. COCH, LNTH, and RMD also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
COCH
Envoy Medical, Inc.
The Income Pick

COCH ranks third and is worth considering specifically for dividends.

  • 14.7% yield, vs MDT's 3.7%, (2 stocks pay no dividend)
Best for: dividends
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 42.9% 10Y total return vs RMD's 293.5%
  • Lower volatility, beta 0.45, Low D/E 0.1%, current ratio 2.70x
  • +15.7% vs COCH's -58.3%
Best for: long-term compounding and sleep-well-at-night
MDT
Medtronic plc
The Income Pick

MDT has the current edge in this matchup, primarily because of its strength in income & stability and defensive.

  • Dividend streak 36 yrs, beta 0.42, yield 3.7%
  • Beta 0.42, yield 3.7%, current ratio 1.85x
  • Lower P/E (13.8x vs 16.0x)
  • 175.8% ROA vs COCH's -256.7%
Best for: income & stability and defensive
RMD
ResMed Inc.
The Value Pick

RMD is the clearest fit if your priority is valuation efficiency.

  • PEG 1.07 vs MDT's 35.17
  • 27.4% margin vs COCH's -98.6%
Best for: valuation efficiency
BSX
Boston Scientific Corporation
The Growth Play

BSX is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
  • 19.9% revenue growth vs LNTH's 0.5%
  • Beta 0.30 vs COCH's 0.95
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthBSX logoBSX19.9% revenue growth vs LNTH's 0.5%
ValueMDT logoMDTLower P/E (13.8x vs 16.0x)
Quality / MarginsRMD logoRMD27.4% margin vs COCH's -98.6%
Stability / SafetyBSX logoBSXBeta 0.30 vs COCH's 0.95
DividendsCOCH logoCOCH14.7% yield, vs MDT's 3.7%, (2 stocks pay no dividend)
Momentum (1Y)LNTH logoLNTH+15.7% vs COCH's -58.3%
Efficiency (ROA)MDT logoMDT175.8% ROA vs COCH's -256.7%

COCH vs LNTH vs MDT vs RMD vs BSX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

COCHEnvoy Medical, Inc.
FY 2025
Other Operating Segment
100.0%$874,000
LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B
RMDResMed Inc.
FY 2024
Sleep And Respiratory
87.5%$4.1B
Software As Service
12.5%$584M
BSXBoston Scientific Corporation
FY 2025
Cardiovascular
66.0%$13.3B
MedSurg
34.0%$6.8B

COCH vs LNTH vs MDT vs RMD vs BSX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGBSX

Income & Cash Flow (Last 12 Months)

RMD leads this category, winning 3 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 147236.5x COCH's $241,000. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to COCH's -98.6%. On growth, COCH holds the edge at +78.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCOCH logoCOCHEnvoy Medical, In…LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.BSX logoBSXBoston Scientific…
RevenueTrailing 12 months$241,000$1.5B$35.5B$5.5B$20.1B
EBITDAEarnings before interest/tax-$22M$347M$9.4B$2.1B$4.7B
Net IncomeAfter-tax profit-$24M$279M$4.6B$1.5B$2.9B
Free Cash FlowCash after capex-$18M$372M$5.4B$1.8B$3.6B
Gross MarginGross profit ÷ Revenue-2.6%+60.5%+61.9%+61.7%+69.0%
Operating MarginEBIT ÷ Revenue-92.4%+18.8%+17.9%+34.3%+19.8%
Net MarginNet income ÷ Revenue-98.6%+18.0%+13.0%+27.4%+14.4%
FCF MarginFCF ÷ Revenue-76.3%+24.0%+15.2%+31.7%+18.1%
Rev. Growth (YoY)Latest quarter vs prior year+78.6%+1.2%+8.8%+10.8%+15.9%
EPS Growth (YoY)Latest quarter vs prior year+25.0%+76.5%-11.9%+9.3%+18.5%
RMD leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 4 of 7 comparable metrics.

At 21.1x trailing earnings, MDT trades at a 24% valuation discount to BSX's 27.8x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.

MetricCOCH logoCOCHEnvoy Medical, In…LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.BSX logoBSXBoston Scientific…
Market CapShares × price$13M$6.1B$97.6B$30.1B$80.1B
Enterprise ValueMkt cap + debt − cash$10M$5.7B$123.9B$29.8B$90.5B
Trailing P/EPrice ÷ TTM EPS-0.51x27.29x21.09x21.74x27.80x
Forward P/EPrice ÷ next-FY EPS est.17.70x13.80x18.61x15.96x
PEG RatioP/E ÷ EPS growth rate35.17x1.25x
EV / EBITDAEnterprise value multiple14.96x14.06x15.49x24.25x
Price / SalesMarket cap ÷ Revenue54.66x3.93x2.91x5.85x3.99x
Price / BookPrice ÷ Book value/share5.84x2.04x5.10x3.29x
Price / FCFMarket cap ÷ FCF17.11x18.83x18.13x21.91x
MDT leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

Evenly matched — LNTH and RMD each lead in 4 of 9 comparable metrics.

RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $9 for MDT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs COCH's 3/9, reflecting strong financial health.

MetricCOCH logoCOCHEnvoy Medical, In…LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.BSX logoBSXBoston Scientific…
ROE (TTM)Return on equity+24.3%+9.4%+24.4%+12.4%
ROA (TTM)Return on assets-2.6%+12.4%+175.8%+18.0%+6.9%
ROICReturn on invested capital+30.6%+6.0%+22.8%+8.8%
ROCEReturn on capital employed-44.7%+17.1%+7.5%+25.7%+11.1%
Piotroski ScoreFundamental quality 0–935687
Debt / EquityFinancial leverage0.00x0.59x0.14x0.51x
Net DebtTotal debt minus cash-$3M-$358M$26.3B-$358M$10.4B
Cash & Equiv.Liquid assets$4M$359M$2.2B$1.2B$2.0B
Total DebtShort + long-term debt$919,000$738,000$28.5B$852M$12.4B
Interest CoverageEBIT ÷ Interest expense-5.82x15.83x9.08x66.06x11.03x
Evenly matched — LNTH and RMD each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LNTH leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $43,814 today (with dividends reinvested), compared to $651 for COCH. Over the past 12 months, LNTH leads with a +15.7% total return vs COCH's -58.3%. The 3-year compound annual growth rate (CAGR) favors BSX at 0.5% vs COCH's -60.3% — a key indicator of consistent wealth creation.

MetricCOCH logoCOCHEnvoy Medical, In…LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.BSX logoBSXBoston Scientific…
YTD ReturnYear-to-date-9.0%+38.3%-20.0%-15.3%-43.1%
1-Year ReturnPast 12 months-58.3%+15.7%-5.5%-14.0%-47.8%
3-Year ReturnCumulative with dividends-93.7%-1.9%-6.3%-8.4%+1.5%
5-Year ReturnCumulative with dividends-93.5%+338.1%-29.2%+12.0%+24.7%
10-Year ReturnCumulative with dividends-93.5%+4289.6%+24.3%+293.5%+143.6%
CAGR (3Y)Annualised 3-year return-60.3%-0.6%-2.1%-2.9%+0.5%
LNTH leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LNTH and BSX each lead in 1 of 2 comparable metrics.

BSX is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than COCH's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 98.1% from its 52-week high vs COCH's 33.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCOCH logoCOCHEnvoy Medical, In…LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.BSX logoBSXBoston Scientific…
Beta (5Y)Sensitivity to S&P 5000.95x0.45x0.42x0.65x0.30x
52-Week HighHighest price in past year$1.91$94.86$106.33$293.81$109.50
52-Week LowLowest price in past year$0.36$47.25$75.91$198.64$53.64
% of 52W HighCurrent price vs 52-week peak+33.2%+98.1%+71.6%+70.4%+49.3%
RSI (14)Momentum oscillator 0–10045.369.929.233.335.4
Avg Volume (50D)Average daily shares traded235K872K7.9M1.1M15.6M
Evenly matched — LNTH and BSX each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — COCH and MDT each lead in 1 of 2 comparable metrics.

Analyst consensus: LNTH as "Buy", MDT as "Buy", RMD as "Buy", BSX as "Buy". Consensus price targets imply 69.3% upside for BSX (target: $91) vs 6.7% for LNTH (target: $99). For income investors, COCH offers the higher dividend yield at 14.65% vs RMD's 1.02%.

MetricCOCH logoCOCHEnvoy Medical, In…LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.BSX logoBSXBoston Scientific…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$99.25$109.50$281.29$91.33
# AnalystsCovering analysts17493543
Dividend YieldAnnual dividend ÷ price+14.7%+3.7%+1.0%
Dividend StreakConsecutive years of raises0036140
Dividend / ShareAnnual DPS$0.09$2.78$2.11
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.0%+3.3%+1.0%0.0%
Evenly matched — COCH and MDT each lead in 1 of 2 comparable metrics.
Key Takeaway

RMD leads in 1 of 6 categories (Income & Cash Flow). MDT leads in 1 (Valuation Metrics). 3 tied.

Best OverallLantheus Holdings, Inc. (LNTH)Leads 1 of 6 categories
Loading custom metrics...

COCH vs LNTH vs MDT vs RMD vs BSX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is COCH or LNTH or MDT or RMD or BSX a better buy right now?

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — COCH or LNTH or MDT or RMD or BSX?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Boston Scientific Corporation at 27. 8x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 07x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — COCH or LNTH or MDT or RMD or BSX?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +338. 1%, compared to -93. 5% for Envoy Medical, Inc. (COCH). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus COCH's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — COCH or LNTH or MDT or RMD or BSX?

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

30β versus Envoy Medical, Inc. 's 0. 95β — meaning COCH is approximately 218% more volatile than BSX relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — COCH or LNTH or MDT or RMD or BSX?

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — COCH or LNTH or MDT or RMD or BSX?

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -98. 6% for Envoy Medical, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -92. 4% for COCH. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is COCH or LNTH or MDT or RMD or BSX more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 07x versus Medtronic plc's 35. 17x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 18. 6x for ResMed Inc. — 4. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 69. 3% to $91. 33.

08

Which pays a better dividend — COCH or LNTH or MDT or RMD or BSX?

In this comparison, COCH (14.

7% yield), MDT (3. 7% yield), RMD (1. 0% yield) pay a dividend. LNTH, BSX do not pay a meaningful dividend and should not be held primarily for income.

09

Is COCH or LNTH or MDT or RMD or BSX better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 7% yield). Both have compounded well over 10 years (MDT: +24. 3%, COCH: -93. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between COCH and LNTH and MDT and RMD and BSX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COCH is a small-cap income-oriented stock; LNTH is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; RMD is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. COCH, MDT, RMD pay a dividend while LNTH, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

COCH

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 39%
  • Dividend Yield > 5.8%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

RMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen
Stocks Like

BSX

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform COCH and LNTH and MDT and RMD and BSX on the metrics below

Revenue Growth>
%
(COCH: 78.6% · LNTH: 1.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.